Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

vaccine reimbursement

Person_Swimming

Why clinical innovation doesn’t translate into real-life outcomes

We’ve made extraordinary progress in healthcare. However, outcomes depend on whether people can make treatment work in their lives.

Mednet

- PMLiVE

Strategies to enhance the provider and patient EAP experience

Expanded access programs (EAPs) play a multifaceted role in the drug development life cycle, serving as a critical bridge between clinical trials and commercial availability.

Uniphar

- PMLiVE

Biogen agrees $850m felzartamab rights deal with TJ Biopharma

The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases

- PMLiVE

myTomorrows partners with Rare Disease Research to boost rare disease referrals

The collaboration aims to improve patient identification and access to clinical trials

- PMLiVE

Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes

The treatment can be used to delay the onset of clinical type 1 diabetes

- PMLiVE

Helus Pharma appoints Ken Kramer as Senior VP, Medical Affairs

Kramer most recently served as VP and Head of Medical Neuroscience at Bristol Myers Squibb

- PMLiVE

Why the field is critical tonext-generation marketing

AI is fundamentally changing the way marketing operates omnichannel journeys, enabling true next-best communication

- PMLiVE

AstraZeneca reports positive phase 3 data for tozorakimab in COPD

COPD affects nearly 400 million people globally and is the third leading cause of death worldwide

- PMLiVE

AI-powered launches on a limited budget: a playbook for emerging biopharma

Every AI decision must drive better outcomes and add greater value for clients

Person on phone

The gap between hype and reality, what patients really say about weight loss drugs

Explore real patient conversations about weight loss drugs, uncovering challenges, support strategies, and the critical need for clear, reliable healthcare communication.

Cuttsy + Cuttsy

- PMLiVE

Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn

The acquisition will help Lilly to expand its capabilities in cell and gene therapy

- PMLiVE

MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment

SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links